Pharma BD Deal Intelligence
Merck & Co. Inc. / Proxygen GmbH
2023 · Licensing/Option · $2.5B · Complete
Announcement Sentiment
83
Strongly positive
Outcome Score
63
Largely worked — most objectives met.
Merck entered a multi-year collaboration with Proxygen to discover and develop novel molecular glue degraders against multiple therapeutic targets.
Key facts
- Announced Apr 05, 2023
- Closed Apr 05, 2023
- Deal value $2.5B
- Deal type Licensing/Option
- Key assets Molecular glue degraders (platform)
- Mechanism Molecular glue degrader (targeted protein degradation)
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals